AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03544684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of the type of exercise on blood glucose concentrations
Description: glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
Study NCT05994404 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical Laminoplasty
Study NCT01094379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
Study NCT01094379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single incision laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy using one entry site to the abdominal cavity
Study NCT02695303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT01398995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of basal insulin infusion to 50% of normal
Description: Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
Study NCT04310033 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
Study NCT03598010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actitan-F (7dd)
Description: 1 sack every 4 hours, maximum 4 sacks/day for 7 days.
Study NCT03598010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actitan-F (28dd)
Description: 1 sack every 4 hours, maximum 4 sacks/day for 28 days.
Study NCT03102645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
Study NCT03102645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine Hydrochloride 25 MG
Description: Two Imipramin DAK film coated tablets 25 mg each, single dose
Study NCT01045408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Berry extract
Description: Berry extract for weeks
Study NCT03069001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir-Simeprevir
Description: -Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
Study NCT03069001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir-Ribavirin
Description: -Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
Study NCT01498029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
Study NCT01806441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-days high fat diet
Description: During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
Study NCT01806441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-days low fat diet
Description: During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
Study NCT01498029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartilage Autograft Implantation System (CAIS)
Description: The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
Study NCT01414504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar + PPV
Description: 0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
Study NCT01414504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infant PCV (Prevenar) + PPV at 9 months
Description: 0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
Study NCT01414504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: No Prevenar + PPV at 9 months
Description: no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
Study NCT01414504 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: control, 0.1mL Pneumovax at 3-5yrs
Study NCT02575859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant HIPEC
Description: Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
Study NCT02575859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
Study NCT03028038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed.
Study NCT03028038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Platelet Rich Plasma
Description: No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed.
Study NCT03022279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Blocks
Description: ultrasound guided transversus abdominis plane block utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
Study NCT03022279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local wound infiltration
Description: local anesthesia provided at the surgical site utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
Study NCT00462332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Induction therapy
Study NCT00462332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Induction therapy
Study NCT00462332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplant
Description: Post-induction therapy
Study NCT00462332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Post-induction therapy
Study NCT02867878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Study NCT02867878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Study NCT04506229 — intervention group
Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: MoCA survey to evaluate cognitive function in COVID-19 positive cases with vs without neurological symptoms
Study NCT00723736 — intervention group
Intervention type: DRUG
Intervention: Desloratadine
Description: 2.5 ml (1.25 mg) once daily
Study NCT03366623 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hospital clown
Description: Presence of the hospital clown
Study NCT03366623 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No hospital clown intervention
Description: Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
Study NCT01340638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cookgas mask
Description: This group will be assigned to use cookgas mask
Study NCT01340638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA mask
Description: LMA mask
Study NCT03865264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recovery Enhancement Program
Description: Behavioral, nutritional, physical and opioid-reduction pain medication
Study NCT05187468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: 1000 pulses at 60 mj, 10 Hz
Study NCT05187468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: 2000 pulses at 60 mj, 10 Hz
Study NCT05187468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy, Massage, Heat pack
Description: Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
Study NCT04268290 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Single incision plus one port laparoscopic surgery
Description: SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
Study NCT03075410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3036656
Description: GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
Study NCT03075410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
Study NCT02652923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid; Perflubutane for Injection
Description: subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
Study NCT00628264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP214
Description: Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
Study NCT00628264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
Study NCT03743467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical evaluation of vision and eye tests
Description: * VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer
Study NCT04307251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navio™ Robotics-assisted Surgical System, LEGION Total Knee System
Description: Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
Study NCT04307251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional, LEGION Total Knee System
Description: Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
Study NCT02377141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Band Ligation
Description: Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
Study NCT02377141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transjugular Intrahepatic Porto-Systemic Stent Shunt
Description: Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
Study NCT01074216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)
Description: Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
Study NCT02769377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breeze2 glucometer
Description: Breeze2 glucometer for self-monitoring of blood glucose
Study NCT02769377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breeze2 glucometer
Description: Breeze2 glucometer for self-monitoring of blood glucose
Study NCT02769377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breeze2 glucometer and H2
Description: Breeze2 glucometer and Health2Sync Mobile App for data transfer
Study NCT02757027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Crystalloid
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study NCT02757027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous HES
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study NCT02119845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular AVF (EndoAVF)
Description: The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
Study NCT04646954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Host DNA methylation testing
Description: Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
Study NCT04646954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cervical cytology and/or high-risk human papillomavirus assays
Description: Cervical cytology and/or high-risk human papillomavirus assays
Study NCT01374373 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Epoetin alfa
Description: Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
Study NCT04304573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total serum calcium blood test
Description: Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
Study NCT02925013 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling for lipid profile
Study NCT02925013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for lipid profile
Study NCT02925013 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary- Normal western diet
Description: Normal western diet
Study NCT02925013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary- Normal western diet
Description: Normal western diet
Study NCT00681785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparine (Fragmin)
Description: transurethrals surgery with and without dalteparine
Study NCT00681785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalteparine (Fragmin)
Description: transurethrals surgery with and without dalteparine
Study NCT01585987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01585987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive care (BSC)
Study NCT00309296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation
Description: This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
Study NCT00309296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation
Description: This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
Study NCT01998087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Description: A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
Study NCT01998087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding support
Description: A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
Study NCT02594605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
Study NCT02594605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Flap Surgery
Description: Only Conventional Flap Surgery treatment the bone loss limitedly.
Study NCT01759407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine
Study NCT01759407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Study NCT02377804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
Study NCT02377804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
Study NCT02377804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
Study NCT02377804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stainless steel needles (0.3mm x 50mm)
Study NCT01457547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)
Description: Three doses administered intramuscularly
Study NCT01457547 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)
Description: Three doses administered intramuscularly